Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism.

Aalbers BL, Yaakov Y, Derichs N, Simmonds NJ, De Wachter E, Melotti P, De Boeck K, Leal T, Tümmler B, Wilschanski M, Bronsveld I.

J Cyst Fibros. 2019 Jul 19. pii: S1569-1993(19)30822-7. doi: 10.1016/j.jcf.2019.07.001. [Epub ahead of print]

PMID:
31331863
2.

Primary sclerosing cholangitis is associated with abnormalities in CFTR.

Werlin S, Scotet V, Uguen K, Audrezet MP, Cohen M, Yaakov Y, Safadi R, Ilan Y, Konikoff F, Galun E, Mizrahi M, Slae M, Sayag S, Cohen-Cymberknoh M, Wilschanski M, Ferec C.

J Cyst Fibros. 2018 Sep;17(5):666-671. doi: 10.1016/j.jcf.2018.04.005. Epub 2018 May 26.

PMID:
29807875
3.

Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function.

Wilschanski M, Yaakov Y, Omari I, Zaman M, Martin CR, Cohen-Cymberknoh M, Shoseyov D, Kerem E, Dasilva D, Sheth S, Uluer A, OʼSullivan BP, Freedman S.

J Pediatr Gastroenterol Nutr. 2016 Nov;63(5):e92-e97.

PMID:
27496797
4.

Human exposure to environmental health concern by types of urban environment: The case of Tel Aviv.

Schnell I, Potchter O, Yaakov Y, Epstein Y.

Environ Pollut. 2016 Jan;208(Pt A):58-65. doi: 10.1016/j.envpol.2015.08.040. Epub 2015 Sep 4.

PMID:
26344491
5.

Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice.

Rosen C, Shezen E, Aronovich A, Klionsky YZ, Yaakov Y, Assayag M, Biton IE, Tal O, Shakhar G, Ben-Hur H, Shneider D, Vaknin Z, Sadan O, Evron S, Freud E, Shoseyov D, Wilschanski M, Berkman N, Fibbe WE, Hagin D, Hillel-Karniel C, Krentsis IM, Bachar-Lustig E, Reisner Y.

Nat Med. 2015 Aug;21(8):869-79. doi: 10.1038/nm.3889. Epub 2015 Jul 13.

PMID:
26168294
6.

Genetic and electrophysiological characteristics of recurrent acute pancreatitis.

Werlin S, Konikoff FM, Halpern Z, Barkay O, Yerushalmi B, Broide E, Santo E, Shamir R, Shaoul R, Shteyer E, Yaakov Y, Cohen M, Kerem E, Ruszniewski P, Masson E, Ferec C, Wilschanski M.

J Pediatr Gastroenterol Nutr. 2015 May;60(5):675-9. doi: 10.1097/MPG.0000000000000623.

PMID:
25383785
7.

Exposure of motorcycle, car and bus commuters to carbon monoxide on a main road in the Tel Aviv metropolitan area, Israel.

Potchter O, Oz M, Brenner S, Yaakov Y, Schnell I.

Environ Monit Assess. 2014 Dec;186(12):8413-24. doi: 10.1007/s10661-014-4013-1. Epub 2014 Aug 30.

PMID:
25171896
8.

The effects of exposure to environmental factors on Heart Rate Variability: an ecological perspective.

Schnell I, Potchter O, Epstein Y, Yaakov Y, Hermesh H, Brenner S, Tirosh E.

Environ Pollut. 2013 Dec;183:7-13. doi: 10.1016/j.envpol.2013.02.005. Epub 2013 Mar 9.

PMID:
23477780
9.

Influence of perfusate temperature on nasal potential difference.

Bronsveld I, Vermeulen F, Sands D, Leal T, Leonard A, Melotti P, Yaakov Y, de Nooijer R, De Boeck K, Sermet I, Wilschanski M, Middleton PG; European Cystic Fibrosis Society – Diagnostic Network Working Group.

Eur Respir J. 2013 Aug;42(2):389-93. doi: 10.1183/09031936.00097712. Epub 2012 Oct 25.

10.

Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis.

Cohen-Cymberknoh M, Yaakov Y, Shoseyov D, Shteyer E, Schachar E, Rivlin J, Bentur L, Picard E, Aviram M, Israeli E, Kerem E, Wilschanski M.

Pediatr Pulmonol. 2013 Mar;48(3):229-35. doi: 10.1002/ppul.22586. Epub 2012 May 2.

PMID:
22553157
11.

Urban daily life routines and human exposure to environmental discomfort.

Schnell I, Potchter O, Yaakov Y, Epstein Y, Brener S, Hermesh H.

Environ Monit Assess. 2012 Jul;184(7):4575-90. doi: 10.1007/s10661-011-2286-1. Epub 2011 Aug 9.

PMID:
21826420
12.

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.

Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, Cohen-Cymberknoh M, Miller NL, Reha A, Northcutt VJ, Hirawat S, Donnelly K, Elfring GL, Ajayi T, Kerem E.

Eur Respir J. 2011 Jul;38(1):59-69. doi: 10.1183/09031936.00120910. Epub 2011 Jan 13. Erratum in: Eur Respir J. 2011 Oct;38(4):996. Pugatch, T [corrected to Pugatsch, T].

13.

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.

Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M.

Lancet. 2008 Aug 30;372(9640):719-27. doi: 10.1016/S0140-6736(08)61168-X. Epub 2008 Aug 20.

PMID:
18722008
14.

Nasal potential difference in non-classic cystic fibrosis-long term follow up.

Jaron R, Yaakov Y, Rivlin J, Blau H, Bentur L, Yahav Y, Kerem E, Bibi H, Picard E, Wilschanski M.

Pediatr Pulmonol. 2008 Jun;43(6):545-9. doi: 10.1002/ppul.20807.

PMID:
18433042
15.

Cystic fibrosis transmembrane conductance regulator ion channel function testing in recurrent acute pancreatitis.

Segal I, Yaakov Y, Adler SN, Blau H, Broide E, Santo M, Yahav Y, Klar A, Lerner A, Aviram M, Ellis I, Mountford R, Shteyer E, Kerem E, Wilschanski M.

J Clin Gastroenterol. 2008 Aug;42(7):810-4. doi: 10.1097/MCG.0b013e318156617c.

PMID:
18360295
16.

Reproducibility of nasal potential difference measurements in cystic fibrosis.

Yaakov Y, Kerem E, Yahav Y, Rivlin J, Blau H, Bentur L, Aviram M, Picard E, Bdolah-Abram T, Wilschanski M.

Chest. 2007 Oct;132(4):1219-26. Epub 2007 Sep 21.

PMID:
17890478

Supplemental Content

Loading ...
Support Center